Tejaswini Kulkarni
Overview
Explore the profile of Tejaswini Kulkarni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cui H, Banerjee S, Xie N, Hussain M, Jaiswal A, Liu H, et al.
Nat Commun
. 2025 Feb;
16(1):1761.
PMID: 39971937
Lung macrophages play a pivotal role in pulmonary fibrosis, with monocyte-derived alveolar macrophages driving disease progression. However, the mechanisms regulating their pro-fibrotic behavior and survival remain unclear, and effective therapeutic...
2.
3.
Kulkarni T, Flaherty K, Gupta S, Tu Y, Case A
Ann Am Thorac Soc
. 2024 Oct;
PMID: 39404835
No abstract available.
4.
Kebbe J, Hart S, Kaner R, Kulkarni T, Wollin L, Coeck C, et al.
ERJ Open Res
. 2024 Oct;
10(5).
PMID: 39351380
https://bit.ly/3wFm0th.
5.
Kulkarni T, Newton C, Gupta S, Samara K, Bernstein E
Pulm Ther
. 2024 Jul;
10(3):331-346.
PMID: 39073523
Introduction: Clinical practice guidelines recommend autoimmune serological testing in patients newly diagnosed with interstitial lung disease of apparently unknown cause who may have idiopathic pulmonary fibrosis (IPF), in order to...
6.
Khan S, Danoff S, Kulkarni T, Reichuber J, Shifren A, Shlobin O, et al.
Ann Am Thorac Soc
. 2024 Apr;
21(7):1103-1106.
PMID: 38626420
No abstract available.
7.
Kulkarni T, Criner G, Kass D, Rosas I, Scholand M, Dilling D, et al.
BMC Pulm Med
. 2024 Mar;
24(1):143.
PMID: 38509495
Background: Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) affect a significant proportion of patients with IPF. There are limited data to inform therapeutic strategies for AE-IPF, despite its high mortality....
8.
Kulkarni T, Criner G, Kass D, Rosas I, Scholand M, Dilling D, et al.
Res Sq
. 2024 Mar;
PMID: 38464052
Background: Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) affect a significant proportion of patients with IPF. There are limited data to inform therapeutic strategies for AEIPF, despite its high mortality....
9.
Kawano-Dourado L, Kulkarni T, Ryerson C, Rivera-Ortega P, Baldi B, Chaudhuri N, et al.
Thorax
. 2024 Mar;
79(8):788-795.
PMID: 38448221
Background: Fibrotic interstitial lung diseases (fILDs) are a heterogeneous group of lung diseases associated with significant morbidity and mortality. Despite a large increase in the number of clinical trials in...
10.
Sridhar M, Bodduluri S, OHare L, Blumhoff S, Acosta Lara M, de Andrade J, et al.
Respir Res
. 2024 Feb;
25(1):81.
PMID: 38326848
Idiopathic pulmonary fibrosis (IPF) is a progressive disease associated with high mortality. Low muscle mass, frailty and sarcopenia lead to functional impairment that negatively impact quality of life and survival...